NCT03975543 (PHENOROD1) is a clinical trial in Retinitis Pigmentosa (RP), sponsored by SparingVision.

Who is sponsoring NCT03975543?

NCT03975543 is sponsored by SparingVision.

What condition does NCT03975543 study?

NCT03975543 studies Retinitis Pigmentosa (RP).

Is NCT03975543 still recruiting?

NCT03975543 is currently status unknown. Last updated 4 August 2021.

Last reviewed 2021-08-04 · How we verify

NCT03975543: PHENOROD1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Retrospective Natural History Study of Retinitis Pigmentosa

Status unknown Last updated 4 August 2021

What this trial tests

trial in Retinitis Pigmentosa (RP) in 113 participants. Status unknown.

Timeline

1 October 2018

Primary endpoint
1 October 2019

30 September 2021

Quick facts

Lead sponsor	SparingVision
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	113
Start date	1 October 2018
Primary completion	1 October 2019
Estimated completion	30 September 2021
Sites	1 location across France

Conditions studied

Retinitis Pigmentosa (RP) — all drugs for Retinitis Pigmentosa (RP) →

Sponsor

SparingVision — full company profile →

Who can join

Eligibility, any sex, with Retinitis Pigmentosa (RP). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is natural history study of rods and cones degenerations in patients with Retinitis Pigmentosa (RP) caused by pathogenic mutations in RHO, PDE6A or PDE6B gene mutations.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Moving Towards PDE6A Gene Supplementation Therapy.
Bujakowska KM, Comander J. · · 2020 · cited 1× · PMID 33057571 · DOI 10.1001/jamaophthalmol.2020.4216

Verify or expand the search:

Other recruiting trials for Retinitis Pigmentosa (RP)

Currently open trials in the same condition.

NCT07266584 — Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration · NA · recruiting
NCT07341919 — Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases · Phase 1, PHASE2 · active not recruiting
NCT07348588 — Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases · Phase 1, PHASE2 · active not recruiting

Other SparingVision trials

Trials by the same sponsor.

NCT04285398 — Prospective Natural History Study of Retinitis Pigmentosa · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03975543 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SparingVision
Last refreshed: 4 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03975543.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing